232 related articles for article (PubMed ID: 30818011)
1. Liposome-targeted recombinant human acid sphingomyelinase: Production, formulation, and in vitro evaluation.
Aldosari MH; de Vries RP; Rodriguez LR; Hesen NA; Beztsinna N; van Kuilenburg ABP; Hollak CEM; Schellekens H; Mastrobattista E
Eur J Pharm Biopharm; 2019 Apr; 137():185-195. PubMed ID: 30818011
[TBL] [Abstract][Full Text] [Related]
2. Nonclinical safety assessment of recombinant human acid sphingomyelinase (rhASM) for the treatment of acid sphingomyelinase deficiency:the utility of animal models of disease in the toxicological evaluation of potential therapeutics.
Murray JM; Thompson AM; Vitsky A; Hawes M; Chuang WL; Pacheco J; Wilson S; McPherson JM; Thurberg BL; Karey KP; Andrews L
Mol Genet Metab; 2015 Feb; 114(2):217-25. PubMed ID: 25092414
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary delivery of recombinant acid sphingomyelinase improves clearance of lysosomal sphingomyelin from the lungs of a murine model of Niemann-Pick disease.
Ziegler RJ; Brown C; Barbon CM; D'Angona AM; Schuchman EH; Andrews L; Thurberg BL; McPherson JM; Karey KP; Cheng SH
Mol Genet Metab; 2009 May; 97(1):35-42. PubMed ID: 19231265
[TBL] [Abstract][Full Text] [Related]
4. Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency.
Wasserstein MP; Jones SA; Soran H; Diaz GA; Lippa N; Thurberg BL; Culm-Merdek K; Shamiyeh E; Inguilizian H; Cox GF; Puga AC
Mol Genet Metab; 2015; 116(1-2):88-97. PubMed ID: 26049896
[TBL] [Abstract][Full Text] [Related]
5. Mannose 6-phosphate receptor-mediated uptake is defective in acid sphingomyelinase-deficient macrophages: implications for Niemann-Pick disease enzyme replacement therapy.
Dhami R; Schuchman EH
J Biol Chem; 2004 Jan; 279(2):1526-32. PubMed ID: 14557264
[TBL] [Abstract][Full Text] [Related]
6. Characterization of human acid sphingomyelinase purified from the media of overexpressing Chinese hamster ovary cells.
He X; Miranda SR; Xiong X; Dagan A; Gatt S; Schuchman EH
Biochim Biophys Acta; 1999 Jul; 1432(2):251-64. PubMed ID: 10407147
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of recombinant acid sphingomyelinase administration by different routes in niemann-pick disease mice.
Bae JS; Jang KH; Schuchman TR; Jin HK
Exp Anim; 2004 Oct; 53(5):417-21. PubMed ID: 15516789
[TBL] [Abstract][Full Text] [Related]
8. Lysosomal involvement in cellular turnover of plasma membrane sphingomyelin.
Sutrina SL; Chen WW
Biochim Biophys Acta; 1984 Apr; 793(2):169-79. PubMed ID: 6424713
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of acid sphingomyelinase activity by lysosomal lipids and sphingolipid activator proteins.
Linke T; Wilkening G; Lansmann S; Moczall H; Bartelsen O; Weisgerber J; Sandhoff K
Biol Chem; 2001 Feb; 382(2):283-90. PubMed ID: 11308026
[TBL] [Abstract][Full Text] [Related]
10. Novel first-dose adverse drug reactions during a phase I trial of olipudase alfa (recombinant human acid sphingomyelinase) in adults with Niemann-Pick disease type B (acid sphingomyelinase deficiency).
McGovern MM; Wasserstein MP; Kirmse B; Duvall WL; Schiano T; Thurberg BL; Richards S; Cox GF
Genet Med; 2016 Jan; 18(1):34-40. PubMed ID: 25834946
[TBL] [Abstract][Full Text] [Related]
11. Degradation of fluorescent and radiolabelled sphingomyelins in intact cells by a non-lysosomal pathway.
Levade T; Vidal F; Vermeersch S; Andrieu N; Gatt S; Salvayre R
Biochim Biophys Acta; 1995 Oct; 1258(3):277-87. PubMed ID: 7548198
[TBL] [Abstract][Full Text] [Related]
12. Accurate differentiation of neuronopathic and nonneuronopathic forms of Niemann-Pick disease by evaluation of the effective residual lysosomal sphingomyelinase activity in intact cells.
Graber D; Salvayre R; Levade T
J Neurochem; 1994 Sep; 63(3):1060-8. PubMed ID: 8051547
[TBL] [Abstract][Full Text] [Related]
13. Infusion of recombinant human acid sphingomyelinase into niemann-pick disease mice leads to visceral, but not neurological, correction of the pathophysiology.
Miranda SR; He X; Simonaro CM; Gatt S; Dagan A; Desnick RJ; Schuchman EH
FASEB J; 2000 Oct; 14(13):1988-95. PubMed ID: 11023983
[TBL] [Abstract][Full Text] [Related]
14. A lipid analogue that inhibits sphingomyelin hydrolysis and synthesis, increases ceramide, and leads to cell death.
Darroch PI; Dagan A; Granot T; He X; Gatt S; Schuchman EH
J Lipid Res; 2005 Nov; 46(11):2315-24. PubMed ID: 16150832
[TBL] [Abstract][Full Text] [Related]
15. Clearance of Hepatic Sphingomyelin by Olipudase Alfa Is Associated With Improvement in Lipid Profiles in Acid Sphingomyelinase Deficiency.
Thurberg BL; Wasserstein MP; Jones SA; Schiano TD; Cox GF; Puga AC
Am J Surg Pathol; 2016 Sep; 40(9):1232-42. PubMed ID: 27340749
[TBL] [Abstract][Full Text] [Related]
16. An enzymatic assay for quantifying sphingomyelin in tissues and plasma from humans and mice with Niemann-Pick disease.
He X; Chen F; Gatt S; Schuchman EH
Anal Biochem; 2001 Jun; 293(2):204-11. PubMed ID: 11399033
[TBL] [Abstract][Full Text] [Related]
17. Retroviral-mediated transfer of the human acid sphingomyelinase cDNA: correction of the metabolic defect in cultured Niemann-Pick disease cells.
Suchi M; Dinur T; Desnick RJ; Gatt S; Pereira L; Gilboa E; Schuchman EH
Proc Natl Acad Sci U S A; 1992 Apr; 89(8):3227-31. PubMed ID: 1565614
[TBL] [Abstract][Full Text] [Related]
18. Uptake and intracellular degradation of fluorescent sphingomyelin by fibroblasts from normal individuals and a patient with Niemann-Pick disease.
Levade T; Gatt S
Biochim Biophys Acta; 1987 Apr; 918(3):250-9. PubMed ID: 3567213
[TBL] [Abstract][Full Text] [Related]
19. Identification of a Novel Acid Sphingomyelinase Activity Associated with Recombinant Human Acid Ceramidase.
He X; Schuchman EH
Biomolecules; 2023 Nov; 13(11):. PubMed ID: 38002305
[TBL] [Abstract][Full Text] [Related]
20. Acid Sphingomyelinase, a Lysosomal and Secretory Phospholipase C, Is Key for Cellular Phospholipid Catabolism.
Breiden B; Sandhoff K
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
